NPCE Neuropace
Neuropace earnings company data as of 7:49 PM ET 10/23
Limited consensus data for this ticker (thin coverage or data-plan limits).
Dates may be company-announced rather than sell-side consensus.
Calendar and recent prints remain the primary lens when available.
Scheduled
1 period, newest first, nothing reported yet. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 3 Nov | EPS | — | — | — |
| Rev | — | — | — |
Insider trades
Open-market buys and sales by NPCE's executives, directors and 10% owners in the last 12 months, from their Form 4s
- None no insider bought on the open market
- None no sales outside a trading plan
- $399K sold by 1 insider under 10b5-1 plans
-
Martha Morrell Chief Medical OfficerPlanned sale$399K 25,000 shares at $15.97 33% of stakeTraded Dec 15, 2025 Filed Mar 4
Also filed in the last 12 months, not counted as buying or selling: 20 stock grants and 19 share withholdings for taxes.
SEC filings
Recent issuer filings from EDGAR, 12 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 7.01,9.01 | Filing Doc | |
| 8-K | 5.07 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| DEF 14A | Filing Doc | ||
| DEFA14A | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.